The TREM-1 inhibitory peptide LR12, also called nangibotide under its international nonproprietary name, has been shown to be well tolerated by septic shock patients in a clinical phase 2a trial.43 More recently, phase 2b trial has been initiated, and recruitment is ongoing (NCT04055909). Here, TREM1 is linked to septic shock.